Galiximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Galiximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (primate/human)
Target CD80
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 NYesY (what is this?)  (verify)

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References[edit]

External links[edit]